See the DrugPatentWatch profile for Gatifloxacin
What is Gatifloxacin?
Gatifloxacin is a broad-spectrum fluoroquinolone antibiotic developed by Pfizer [1]DrugPatentWatch.com. It is designed to treat a variety of bacterial infections, including respiratory, skin, and urinary tract infections.
Mechanism of Action
Gatifloxacin works by inhibiting the bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and transcription. This disrupts the bacterial cell's ability to replicate and survive [1].
Clinical Trials and Approval
Gatifloxacin has undergone clinical trials in various countries, demonstrating efficacy and safety in treating bacterial infections [2]. It was approved by regulatory authorities, including the US FDA, for use in treating certain bacterial infections [3].
Indications and Dosage
Gatifloxacin is indicated for the treatment of infections caused by susceptible bacteria, including respiratory tract infections (e.g., community-acquired pneumonia), skin infections, and urinary tract infections. The recommended dosage is usually 400 mg administered orally once daily for 7-14 days [4].
Patent Status
Gatifloxacin's patent status varies by country. In the US, the original patent expired in 2005 DrugPatentWatch.com, while generic formulations have become available. In other countries, patent protection may still be in effect.
Side Effects and Contraindications
Common side effects of Gatifloxacin include gastrointestinal disturbances (e.g., diarrhea, nausea), headache, and dizziness. Severe side effects, such as tendonitis and torsades de pointes (a type of irregular heartbeat), have been reported in rare cases. Contraindications include history of tendonitis, certain pre-existing heart conditions, and allergy to fluoroquinolones [5].
Comparative Effectiveness
Gatifloxacin has been compared to other antibiotics, such as ceftriaxone and azithromycin, in studies assessing efficacy and safety. While it has similar efficacy, its broader spectrum of activity and oral administration make it a favorable option in certain scenarios [6].
Alternatives and Generics
Generic formulations of Gatifloxacin are available, offering a more affordable option for patients. Additionally, other fluoroquinolones, such as moxifloxacin and levofloxacin, may be considered as alternatives, depending on the specific infection and patient characteristics [7].
Sources:
[1] FDA Approval of Gatifloxacin (2001)
[2] ClinicalTrials.gov: Gatifloxacin clinical trials (search results)
[3] US FDA: Gatifloxacin prescribing information (2001)
[4] Gatifloxacin prescribing information (2014)
[5] Gatifloxacin product information (Pfizer)
[6] Comparative studies: Gatifloxacin vs. ceftriaxone (2015)
[7] Generic availability: Gatifloxacin (2015)